Seattle, WA -- (SBWIRE) -- 09/23/2019 -- Tuberculosis is a common infectious disease caused by mycobacterium tuberculosis that affects the lungs. The treatment of TB is divided into two types; first line therapy and second line therapy. In first line therapy, TB is treated with drugs such as isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), ethambutol (EMB), and streptomycin (SM). However, first line therapy fails more often in the cases of drug resistant bacterial TB. Tuberculosis is classified into latent tuberculosis and active tuberculosis.
The high burden of TB is driving the growth of this market. For instance, according to the WHO, in 2017, 87% of new TB cases occurred in 30 high TB burden countries. The eight countries out of 30/z include India, China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa which accounted for two thirds of the new TB cases.
Increasing global burden of TB is expected to drive the tuberculosis drugs market growth. For instance, according to the Centre for Disease Control and Prevention, in 2017, 10.0 million people around the world suffered from TB, and there were 1.3 million TB-related deaths worldwide.
Request Sample Copy of the Report: https://www.coherentmarketinsights.com/insight/request-sample/191
Moreover, according to WHO data published in 2018, TB costs the world over US$ 21 billion each year, including US$ 9.2 billion for treatment and prevention, and US$12 billion in additional economic costs and lost productivity. Increasing healthcare spending on treatment of TB is expected to drive growth of the market. Moreover, according to the WHO, treatment for multi-drug resistant TB (MDR-TB) takes 20-26 months, and average cost of treatment in the U.S. is around US$ 294,000.
Moreover, increasing investments in research and development activities are expected to drive growth of the market. According to the Tuberculosis Research Funding Trends 2005-2017 reports, global investment in TB research was valued at US$ 772 Million in 2017 with an increase of 6% (or US$ 46 million), compared to US$726 million in 2016.
Increasing funding and expenditure on TB treatment and research is driving growth of the market. For instance, according to the WHO, the global TB-related funding to 119 emerging economies reached around US$ 6.9 billion in 2018, from US$ 3.3 billion in 2006, where 86% of the total funding is provided by Brazil, Russia, India, China, and South Africa (BRICS).
Ask for customization: https://www.coherentmarketinsights.com/insight/request-customization/191
Furthermore, increasing research and drug development activities are driving growth of the market. For instance, in 2019, the U.S. FDA approved the TB Alliance manufactured drug Pretomanid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs.
Additionally, the tuberculosis drugs market size is expected to witness significant growth, owing to increasing global incidence of TB. For instance, according to the WHO Global Tuberculosis Report 2018, it's estimated that around 10 million people suffered from TB disease in 2017, which included 5.8 million men, 3.2 million women, and 1.0 million children.
Key players operating in this market are adopting collaboration strategies to meet the increasing demand of TB treatment drugs. For instance, in 2015, Dishman Pharmaceuticals and Chemicals Limited entered into license collaboration with Johnson & Johnson to manufacture raw material for drugs used in the treatment of multi drug resistant tuberculosis (MDR-TB).
Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/191
Detailed Segmentation:
By Therapy Type :
First Line Therapy
Isoniazid (INH)
rifampicin (RIF)
Ethambutol (EMB)
Pyrazinamide (PZA)
Streptomycin (SM).
Second Line Therapy
Fluoroquinolones
Injectable antituberculosis drugs
By Disease Type:
Active TB
Latent TB
By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Major players operating in the global tuberculosis drugs market include Johnson & Johnson Services, LLC, Lupin ltd., Novartis AG, Macleods Pharmaceuticals Ltd., Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., and others.
To know more about the Tuberculosis Drugs Market, click the link below: https://www.coherentmarketinsights.com/market-insight/tuberculosis-drugs-market-191
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.